Research also suggests that the effects of cardiometabolic health can be affected following discontinuation of semaglutide use, which can increase risk factors for obesity related diseases such as diabetes and hypertension
Additionally, individuals experiencing certain neurological symptoms or those with high levels of homocysteine, a risk factor for cardiovascular diseases, might find our B12 injections beneficial
The trial also noted side effects, with mild to moderate digestive problems reported most often.The approval comes alongside research from the University of Oxford suggesting that people using drugs such as semaglutide, sold as Wegovy, and tirzepatide, marketed as Mounjaro, tend to lose weight while on treatment but regain it within about 20 months after stopping the injections
while glycaemic efficacy diminishes at lower eGFR levels, some agents are licensed for heart failure and chronic kidney disease at eGFRs below 30 ml/min/1.73m